AML ARISING FROM MYELODYSPLASTIC SYNDROME (MDS)
Clinical trials for AML ARISING FROM MYELODYSPLASTIC SYNDROME (MDS) explained in plain language.
Never miss a new study
Get alerted when new AML ARISING FROM MYELODYSPLASTIC SYNDROME (MDS) trials appear
Sign up with your email to follow new studies for AML ARISING FROM MYELODYSPLASTIC SYNDROME (MDS), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to control rare leukemia without harsh chemo
Disease control OngoingThis Phase 3 trial tests whether adding ivosidenib (a targeted pill) to standard azacitidine helps adults with a specific IDH1-mutated acute myeloid leukemia (AML) who cannot have intensive chemotherapy. About 146 participants receive either the combo or a placebo plus azacitidin…
Matched conditions: AML ARISING FROM MYELODYSPLASTIC SYNDROME (MDS)
Phase: PHASE3 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New drug combo shows promise for genetic subtype of leukemia
Disease control OngoingThis early-stage trial tests two new targeted drugs (AG-120 and AG-221) given alongside standard chemotherapy for people with a specific genetic form of acute myeloid leukemia (AML). The study includes about 153 adults with newly diagnosed AML that has an IDH1 or IDH2 mutation. T…
Matched conditions: AML ARISING FROM MYELODYSPLASTIC SYNDROME (MDS)
Phase: PHASE1 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC